Keeps Prescribing Data and Outcomes Signals: An Independent Review

What Is Keeps and How Does Its Prescribing Model Work?

Keeps operates as an asynchronous telehealth platform: a prospective patient uploads photos of his scalp, answers a short intake questionnaire, and a licensed clinician reviews the case without a live video appointment. If appropriate, the clinician prescribes finasteride 1 mg daily, topical minoxidil, or both. Prescriptions are fulfilled through a contracted pharmacy and shipped by mail.

Asynchronous vs. Synchronous Prescribing

Asynchronous telehealth is legal in most U.S. States for conditions that can be assessed photographically, which includes androgenetic alopecia (AGA). The American Academy of Dermatology notes that standardized scalp photography is an accepted tool for AGA severity grading, though it is not equivalent to in-person dermoscopy. The 2020 AAD guidelines on androgenetic alopecia specify that diagnosis of AGA is primarily clinical, meaning a photograph-based workflow can satisfy that standard when the photographs are adequately standardized.

No published data confirms whether Keeps's photo intake protocol meets AAD standardization criteria. That gap matters because misclassified patients may receive finasteride unnecessarily, while patients with scarring alopecias (which do not respond to finasteride) may be delayed in getting an accurate diagnosis.

State Licensing and Controlled-Substance Restrictions

Finasteride is not a controlled substance, which means prescribing it via asynchronous telehealth is permissible under most state telemedicine statutes. The FDA label for finasteride 1 mg (Propecia) requires documentation of a diagnosis of AGA, but does not mandate in-person examination. Keeps operates in most contiguous U.S. States; patients in states with stricter synchronous-visit requirements may be declined.

Finasteride Efficacy: What the Trial Record Actually Shows

Finasteride 1 mg is the better-evidenced of the two drugs Keeps prescribes. Understanding the underlying trial data is the only way to evaluate whether Keeps's marketing claims are grounded.

The Two-Year Key Trial

The key phase III trial of finasteride 1 mg (N=1,553 men with mild-to-moderate AGA) found that 83% of finasteride-treated men maintained or increased hair count at 24 months, compared with 28% in the placebo group (P<0.001). Mean hair count increased by 107 hairs per 1-cm² target area in finasteride-treated men versus a decrease of 138 hairs in the placebo group. The effect is real and statistically durable.

Five-Year Extension Data

A five-year open-label extension of the same trial, published in the Journal of the American Academy of Dermatology, showed continued benefit through 60 months, with 90% of men maintaining hair count relative to baseline. Men who switched from placebo to finasteride in the extension phase regained hair but never fully caught up to those on continuous therapy, reinforcing early-start arguments.

Sexual Side Effects: What the Label Says

The FDA label reports sexual adverse effects, including decreased libido (1.8% finasteride vs. 1.3% placebo), erectile dysfunction (1.3% vs. 0.7%), and ejaculation disorder (1.2% vs. 0.7%) in the two-year controlled trial. Post-marketing surveillance data submitted to FDA also includes reports of persistent sexual dysfunction after discontinuation, a syndrome sometimes called post-finasteride syndrome. The FDA added a label update in 2012 to reflect these persistent-effect reports. Keeps's intake questionnaire asks about sexual dysfunction history, but the platform's screening rigor for ruling out at-risk patients is not independently audited.

Minoxidil Efficacy: Trial Evidence Behind the Second Drug

Topical minoxidil 5% solution is the other cornerstone of Keeps's prescribing. It is available over the counter in the U.S., meaning Keeps is effectively offering a convenient subscription for a drug patients could buy at a pharmacy without a visit.

The 48-Week Comparative Trial

The 48-week randomized controlled trial comparing 5% and 2% minoxidil in men with AGA (N=393) found that 45% of men using 5% solution rated their regrowth as "moderately" or "greatly" increased versus 7% in the placebo group. The 5% formulation outperformed the 2% formulation on both investigator and patient assessments. A separate Cochrane systematic review of minoxidil for AGA confirmed topical minoxidil's superiority over placebo across 18 trials.

Minoxidil Oral: An Off-Label Signal Worth Knowing

Low-dose oral minoxidil (0.25 to 2.5 mg daily) has emerged as an off-label option studied in a 2021 randomized trial published in JAMA Dermatology (N=90), which showed non-inferiority to 5% topical minoxidil for hair regrowth at 24 weeks. Keeps does not publicly list oral minoxidil as a standard offering, though some clinicians may prescribe it off-label through the platform depending on state rules and patient history.

Scalp Irritation and Hypertrichosis

Common adverse effects of topical minoxidil include contact dermatitis (reported in roughly 7% of users in controlled trials) and facial hypertrichosis from solution transfer. The FDA labeling for topical minoxidil advises patients to wash hands thoroughly after application for this reason.

Combination Therapy: Does Using Both Drugs Add Benefit?

Using finasteride and topical minoxidil together appears to outperform either agent alone based on available evidence. A 52-week randomized trial published in Dermatologic Therapy (N=450) found that combination therapy produced significantly greater increases in hair count and hair weight than monotherapy with either drug. The difference reached statistical significance at 12 months (P<0.001). Keeps's two-drug subscription bundle is therefore supported by trial-level evidence, not just marketing convenience.

Is Keeps Legit? Licensing, Accreditation, and Regulatory Signals

"Is Keeps legit?" is the most common user question about the platform. The answer requires separating several distinct dimensions: legal operation, clinical quality, and consumer protection signals.

Legal Operation and LegitScript Status

LegitScript is the third-party verification service used by Google and major ad platforms to certify online pharmacies and telehealth prescribers. As of the publication date of this article, Keeps holds LegitScript certification, meaning it has passed LegitScript's review of its prescribing and dispensing practices. LegitScript certification does not equal a clinical quality audit, but it does confirm the platform is not operating as a rogue pharmacy.

BBB Profile and Complaint Patterns

The Better Business Bureau profile for Keeps shows the company is not BBB-accredited as of January 2025. The BBB complaint log includes recurring themes: billing disputes (charges continuing after cancellation requests), delayed shipments, and difficulties reaching customer service. These are consumer-experience complaints, not clinical safety reports. The FDA MedWatch database is the appropriate channel for adverse drug event reports; BBB complaints do not indicate FDA enforcement action.

FDA Warning Letters and Enforcement History

A search of FDA's warning letter database as of January 2025 does not return an active warning letter directed at Keeps. That absence does not mean the platform has been affirmatively reviewed and cleared. The FDA does not proactively audit every telehealth prescriber; enforcement is largely complaint-driven.

State Medical Board Oversight

Telehealth prescribers must hold licenses in the states where patients reside. Keeps's clinicians are listed by specialty but not individually named on the platform's public-facing pages, which limits consumers' ability to independently verify board certification or check disciplinary history through state medical board databases. Patients can request the name of their prescribing clinician and then check that clinician's license status through their state's medical board portal, which the Federation of State Medical Boards maintains in a searchable directory.

Keeps Complaints: A Structured Analysis

Consumer complaints about Keeps cluster into four categories based on publicly available reviews on Trustpilot, Reddit, and the BBB. Organizing them this way makes it easier to assess which complaints reflect clinical risk and which reflect operational friction.

Category 1: Billing and Cancellation Disputes

This is the highest-volume complaint category. Users report subscriptions continuing to bill after cancellation requests submitted through the app, and difficulty obtaining refunds. These complaints are operational, not clinical, but they matter: a patient who cannot easily cancel may continue receiving a drug he no longer wants or that his new physician wants to change.

Category 2: Shipping and Fulfillment Delays

Multiple reviews cite 2-to-4 week delays in receiving prescriptions. Finasteride discontinuation does not cause immediate adverse effects, but hair loss progression can resume within 3 to 6 months of stopping therapy, as noted in the original finasteride key trial follow-up data. A 2-to-4 week gap is unlikely to cause measurable loss, but repeated gaps compound.

Category 3: Clinician Access and Follow-Up

Users report difficulty scheduling follow-up consultations and receiving responses to questions about side effects. The asynchronous model by design limits real-time access to a clinician. The ATA (American Telemedicine Association) core operational guidelines recommend that telehealth platforms provide clear pathways for patients to contact a clinician for follow-up concerns. Inadequate follow-up access is a genuine clinical-quality signal, not just a convenience issue.

Category 4: Prescription Changes and Dosing Transparency

A smaller subset of complaints describes prescriptions being changed (e.g., from brand minoxidil to generic) without explicit patient notification. Under FDA regulations, generic substitution is pharmacist-driven and legal when an AB-rated generic exists. Both finasteride generics and minoxidil generics carry AB ratings, confirming bioequivalence. The FDA Orange Book listing for finasteride 1 mg confirms multiple AB-rated generics are approved.

Prescribing Data Transparency: What Keeps Publishes and What It Does Not

Keeps has published its own marketing claim that "9 out of 10 customers see results," but this figure is not sourced to a peer-reviewed publication, a registered clinical trial, or an independently audited internal cohort. No methodology, sample size, follow-up duration, or definition of "results" accompanies the statistic on the platform's public pages. Evaluating this claim requires applying a structured framework:

The HealthRX Telehealth Outcomes Claim Framework

A credible outcomes claim from a telehealth prescriber should satisfy four criteria:

1. Sample size and follow-up: The claim should specify N and the duration at which results were measured (e.g., "83% at 24 months, N=1,553" as in the Merck key trial).
2. Outcome definition: "Results" must be defined. Hair count per cm²? Patient-rated improvement? Photograph-assessed grading scale?
3. Comparator: Results vs. Baseline or vs. Placebo? A self-comparison with no placebo arm overstates treatment effect.
4. Independent verification: Internal survey data is less reliable than a registered clinical trial or a third-party audit.

Keeps's "9 out of 10" claim does not meet any of these four criteria based on publicly available information. The underlying drugs have strong trial support, but platform-specific claims are marketing, not evidence. The distinction is medically significant: trial-proven efficacy for finasteride 1 mg does not automatically validate whatever protocol Keeps uses to select, dose, and monitor patients.

The FDA's guidance on prescription drug advertising specifically flags outcome claims made without adequate scientific substantiation as a red flag in direct-to-consumer drug promotion.

How Keeps Compares to the Underlying Clinical Guidelines

The 2019 ISHRS (International Society of Hair Restoration Surgery) evidence-based guidelines and the 2017 updated AAD guidelines on AGA both recommend finasteride 1 mg daily and topical minoxidil 5% as first-line treatments for men with AGA. On drug selection alone, Keeps is aligned with guideline-recommended therapy.

Where the guidelines go further than Keeps's model: they recommend baseline laboratory assessment in select patients (particularly those with atypical presentation or family history of prostate disease) and periodic follow-up with clinical examination or standardized photography at 6 and 12 months. Whether Keeps's asynchronous model meets those follow-up recommendations depends on individual clinician practice within the platform, which is not publicly documented.

The Endocrine Society's clinical practice guideline on androgen therapy notes that finasteride lowers PSA values by approximately 50%, a fact relevant to men over 40 who are being screened for prostate cancer. Keeps's intake questionnaire does not publicly specify whether it screens for PSA history or advises patients to inform their urologist of finasteride use.

Pricing, Subscription Structure, and Cost Comparison

Keeps charges approximately $25 to $35 per month for generic finasteride 1 mg and $15 to $25 per month for minoxidil solution, depending on the subscription tier. The consultation fee is bundled into the first month's cost. Goodrx data for finasteride 1 mg (30 tablets) at major retail pharmacies shows prices ranging from $12 to $22 per month for the generic, meaning Keeps's markup for the convenience of the telehealth visit is roughly $10 to $15 per month. For patients in states where finasteride requires a written prescription, that markup covers a real service. Patients who already have a prescription could fill it more cheaply at retail.

Who Should and Should Not Use Keeps

Appropriate Candidates

Men aged 18 to 60 with a clear photographic pattern consistent with Norwood scale II through V androgenetic alopecia, no history of sexual dysfunction, no family history of prostate cancer, and no prior adverse reaction to 5-alpha reductase inhibitors are reasonable candidates for the Keeps model. The Norwood-Hamilton classification, the standard staging tool for male AGA, can be reasonably assessed photographically for mid-range presentations.

Patients Who Need In-Person Evaluation First

Men with diffuse hair loss that does not follow the Norwood pattern, rapid onset over <6 months, associated systemic symptoms (fatigue, weight change, or cold intolerance), or scalp inflammation should be evaluated in person before initiating treatment. Diffuse alopecia may signal thyroid dysfunction, iron deficiency, or telogen effluvium, none of which respond to finasteride. The American Academy of Dermatology's patient resource on hair loss lists thyroid disease and nutritional deficiencies as common reversible causes that require laboratory workup, not a D2C prescription.

Men with a first-degree relative with prostate cancer or a personal history of elevated PSA should discuss finasteride use with a urologist before starting, given the FDA's 2011 label update noting an increased proportion of high-grade prostate cancers in men using 5-alpha reductase inhibitors in the PCPT trial (N=18,880).

Practical Steps Before Starting a Keeps Subscription

1. Photograph your scalp under consistent lighting and compare your pattern against a published Norwood scale diagram to determine whether your presentation is typical AGA.
2. Check your prescribing clinician's name in the Keeps app after your consultation and verify their license status at the FSMB DocInfo portal.
3. Inform your primary care physician that you are starting finasteride so they can adjust PSA interpretation accordingly, as finasteride suppresses PSA by roughly 50% and can mask early prostate cancer signals.
4. Set a calendar reminder for a 6-month self-assessment: standardized front, top, and vertex scalp photos under the same lighting, same distance.
5. Screenshot the cancellation confirmation if you ever choose to stop the subscription, given the volume of billing complaints in public review forums.